Cargando…

Determination of Somatic Mutations and Tumor Mutation Burden in Plasma by CAPP-Seq during Afatinib Treatment in NSCLC Patients Resistance to Osimertinib

Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) were developed to target the EGFR T790M resistance mutation in non-small cell lung cancer (NSCLC) patients resistant to first- or second-generation EGFR-TKIs. To investigate the efficacy of afatinib treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ishii, Hidenobu, Azuma, Koichi, Sakai, Kazuko, Naito, Yoshiko, Matsuo, Norikazu, Tokito, Takaaki, Yamada, Kazuhiko, Hoshino, Tomoaki, Nishio, Kazuto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971280/ https://www.ncbi.nlm.nih.gov/pubmed/31959859 http://dx.doi.org/10.1038/s41598-020-57624-4

Ejemplares similares

Effectiveness of afatinib in an NSCLC patient with EGFR mutation and early progression to osimertinib: a case report
por: Nozaki, Koichiro, et al.
Publicado: (2022)

Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients
por: Matsuo, Norikazu, et al.
Publicado: (2016)

Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC
por: Ishii, Hidenobu, et al.
Publicado: (2020)

Pulmonary pleomorphic carcinoma: A case harboring EGFR mutation treated with EGFR‐TKIs
por: Masuda, Ken, et al.
Publicado: (2018)

Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples
por: Ishii, Hidenobu, et al.
Publicado: (2015)

Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial
por: Miura, Satoru, et al.
Publicado: (2023)

Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib
por: Yamamoto, Nobuyuki, et al.
Publicado: (2019)

Accuracy of transbronchial biopsy as a rebiopsy method for patients with relapse of advanced non-small-cell lung cancer after systemic chemotherapy
por: Ishii, Hidenobu, et al.
Publicado: (2017)

The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated EGFR gene contributes to the resistance to afatinib, erlotinib and osimertinib in human lung cancer cells
por: Murakami, Yuichi, et al.
Publicado: (2017)

Is there a role for sequential afatinib and osimertinib in patients with EGFR mutation?
por: Iwamoto, Natsuhiko, et al.
Publicado: (2022)

Phase I study of afatinib plus bevacizumab in patients with advanced non-squamous non-small cell lung cancer harboring EGFR mutations
por: Ko, Ryo, et al.
Publicado: (2021)

Changes in the gene mutation profiles of circulating tumor DNA detected using CAPP-Seq in neoadjuvant chemotherapy-treated advanced ovarian cancer
por: Noguchi, Tomoko, et al.
Publicado: (2020)

Lung Cancer with a Small Cell Carcinoma Component Diagnosed from Pleural Effusion and a Squamous Cell Carcinoma Component Diagnosed from the Tumor
por: Zaizen, Yoshiaki, et al.
Publicado: (2018)

Programmed cell death-ligand 1 expression and immunoscore in stage II and III non-small cell lung cancer patients receiving adjuvant chemotherapy
por: Ishii, Hidenobu, et al.
Publicado: (2017)

Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib
por: Hochmair, Maximilian J., et al.
Publicado: (2018)

Clinical significance of interstitial lung abnormalities and immune checkpoint inhibitor‐induced interstitial lung disease in patients with non‐small cell lung cancer
por: Murata, Daiki, et al.
Publicado: (2022)

Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review
por: Jiang, Yingying, et al.
Publicado: (2023)

Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases
por: Jiang, Tao, et al.
Publicado: (2020)

Prognostic effect of cachexia in patients with non‐small cell lung cancer receiving immune checkpoint inhibitors
por: Matsuo, Norikazu, et al.
Publicado: (2023)

Survival and biomarkers for cachexia in non‐small cell lung cancer receiving immune checkpoint inhibitors
por: Murata, Daiki, et al.
Publicado: (2023)

Hypothesis generative head-to-head study comparing efficacy of afatinib and osimertinib based on immunological biomarkers in Japanese NSCLC patients with EGFR mutations (Heat on Beat study)
por: Morikawa, Kei, et al.
Publicado: (2020)

Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings
por: Harvey, R Donald, et al.
Publicado: (2020)

Significant Benefits of Afatinib and Apatinib in a Refractory Advanced NSCLC Patient Resistant to Osimertinib: A Case Report
por: Zhao, Yuanyang, et al.
Publicado: (2021)

Rechallenge of afatinib for EGFR-mutated non-small cell lung cancer previously treated with osimertinib: a multicenter phase II trial protocol (REAL study)
por: Araki, Taisuke, et al.
Publicado: (2023)

Afatinib and osimertinib in lung adenocarcinoma harbored EGFR T751_I759delinsS mutation: A case report
por: Fang, Yueh‐Fu, et al.
Publicado: (2021)

Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report
por: Liu, Jing, et al.
Publicado: (2019)

Real-World Data About Treatment Outcomes for Patients with EGFR-Mutated NSCLC Resistance to Osimertinib and Platinum-Based Chemotherapy
por: Hayashi, Hidetoshi, et al.
Publicado: (2023)

Comprehensive assessment of pretreatment sarcopenia impacts on patients with EGFR ‐mutated NSCLC treated with afatinib
por: Wu, Chen‐Te, et al.
Publicado: (2023)

Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
por: Lamb, Yvette N.
Publicado: (2021)

Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases
por: Zheng, Mei-Mei, et al.
Publicado: (2022)

Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study
por: Ji, Jingran, et al.
Publicado: (2023)

The potential therapeutic regimen for overcoming resistance to osimertinib due to rare mutations in NSCLC
por: Han, Rui, et al.
Publicado: (2023)

Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M Mutation
por: Watanabe, Kana, et al.
Publicado: (2023)

Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
por: Lin, Ling, et al.
Publicado: (2020)

Efficacy and safety of osimertinib in treating EGFR‐mutated advanced NSCLC: A meta‐analysis
por: Yi, Lilan, et al.
Publicado: (2019)

Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC)
por: Bracht, Jillian Wilhelmina Paulina, et al.
Publicado: (2019)

Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
por: Lamb, Yvette N.
Publicado: (2021)

Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report
por: Crowley, Fionnuala, et al.
Publicado: (2021)

Sarcomatoid Type Primary Pericardial Mesothelioma with a Long-term Survival after the Onset of Cardiac Tamponade
por: Saisho, Chika, et al.
Publicado: (2016)

Clinical significance of plasma-free amino acids and tryptophan metabolites in patients with non-small cell lung cancer receiving PD-1 inhibitor: a pilot cohort study for developing a prognostic multivariate model
por: Azuma, Koichi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fujeu8sp0djklbrlic1hpp69ct